Read more
Multiple sclerosis (MS) is a complex disease with a presumed autoimmune aetiology and few current effective treatments. Disease modifying therapies focus on the altering the natural course of relapsing and remitting MS, targeting the inflammatory response. Other targets involve tacking the cause of the disease - demyelination of axons through remyelination therapies. Due to several recent breakthroughs in the understanding of the pathophysiology of MS new targets for remyelination and immunomodulation are rapidly emerging. This book provides a comprehensive overview of drug discovery and development for the molecular basis of the disease, from new targets to drugs currently in clinical development, cellular and animal disease models to biomarkers for diagnosis and assessment in clinical trials.
Emerging Drugs and Targets for Multiple Sclerosis is an ideal reference for any student or researcher interested in drug development for neurodegenerative diseases, autoimmune diseases and MS in particular.
List of contents
Multiple Sclerosis: Epidemiology, Genetics, Symptoms, and Unmet Needs; Genetics of Multiple Sclerosis; Biomarkers for Multiple Sclerosis; Optical Coherence Tomography in Multiple Sclerosis; Experimental in vivo Models for Drug Discovery in Multiple Sclerosis; Progressive Multiple Sclerosis: Drug Discovery; B Cells-based Therapies for Multiple Sclerosis; Protein Kinase Inhibitors for the Treatment of Multiple Sclerosis; Emerging Drugs and Targets for Remyelination in Multiple Sclerosis; Regulation of Oligodendrocyte Differentiation: New Targets for Drug Discovery in Remyelination; Cannabinoids as a Therapeutic Approach in Multiple Sclerosis; Sigma Receptors as New Target for Multiple Sclerosis; Non-Coding RNA and Multiple Sclerosis: New targets for Drug Discovery; Diet, Gut Microbiome and Multiple Sclerosis
